Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab.

Conclusions: Psoriasis patients treated with guselkumab had significantly better improvements in absenteeism and presenteeism compared with those treated with adalimumab, regardless of depression/anxiety status. PMID: 31305186 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31305186?dopt=Abstract

Source: Journal of Dermatological Treatment - July 16, 2019 Category: Dermatology Tags: J Dermatolog Treat Source Type: research